Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Guardant Health raises $360mm in Series E round

Executive Summary

Guardant Health Inc. (molecular diagnostics for cancer) raised $360mm through its Series E round. A Softbank Group division led and was joined by new investors T. Rowe Price and Temasek, along with returning backers Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, OrbiMed, and 8VC. The funding was announced in tandem with news that Guardant intends to sequence the tumor DNA of over 1mm cancer patients within the next five years. The company has now raised $550mm in venture funding.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies